Guilhou J J, Malbos S, Meynadier J
Ann Dermatol Venereol. 1978 Oct;105(10):813-8.
The aromatic retinoic acid derivative Ro 10-9359 was administered orally to 25 severe psoriatic patients (14 with generalized plaques, 7 erythrodermic, 4 pustular). The initial dose was 25 mg/20 kg body weight daily for 4 weeks; afterwards the same posology was given every other day during several months (Max : 18 months). Excellent results were obtained in 16 patients (64 p. 100) particularly in severe erythrodermic and pustular psoriasis. However, under follow-up therapy relapses sometimes occurred leading to temporary resumption of initial posology. The most important side effects are cheilitis, palmoplantar scaling with thinning of the skin, hyperhidrosis and diffuse hair loss. A slight increase of transaminases and of alkaline phosphatases was found in a few patients. The Ro 10-9359 compound is a very useful new therapy of severe psoriasis.
将芳香维甲酸衍生物Ro 10-9359口服给予25例重度银屑病患者（14例为泛发性斑块状，7例为红皮病型，4例为脓疱型）。初始剂量为每日25mg/20kg体重，共4周；之后在几个月内每隔一天给予相同剂量（最长18个月）。16例患者（64%）取得了优异疗效，尤其是在重度红皮病型和脓疱型银屑病患者中。然而，在后续治疗中有时会出现复发，导致暂时恢复初始剂量。最重要的副作用是唇炎、掌跖部皮肤脱屑伴皮肤变薄、多汗和弥漫性脱发。少数患者发现转氨酶和碱性磷酸酶略有升高。Ro 10-9359化合物是重度银屑病一种非常有用的新疗法。
